Details of the Drug Combinations

General Information of This Drug (ID: DMB920Z)

Drug Name

Ceritinib DMB920Z

Synonyms

ceritinib; LDK378; 1032900-25-6; ZYKADIA; NVP-LDK378-NX; LDK-378; UNII-K418KG2GET; LDK378(Ceritinib); LDK 378; Eritinib (LDK378); 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; K418KG2GET; CHEMBL2403108; CHEBI:78432; AK174337; ceritinib; C28H36ClN5O3S; 5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine; 5-Chloro-N2-(5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl)-N4-(2-(propane-2-sulfonyl)phenyl)pyrim

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

25 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Belinostat + Ceritinib	DCDOIVU	Belinostat	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[2]
Belinostat + Ceritinib	DCKA0RJ	Belinostat	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[2]
Belinostat + Ceritinib	DCI6S7Z	Belinostat	Embryonal rhabdomyosarcoma (Cell Line: RD)	[2]
BGJ398 + Ceritinib	DC84YGE	BGJ398	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[2]
BGJ398 + Ceritinib	DCKO5SS	BGJ398	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[2]
BGJ398 + Ceritinib	DCUR85F	BGJ398	Embryonal rhabdomyosarcoma (Cell Line: RD)	[2]
Ceritinib + Trametinib	DCH0NN5	Trametinib	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[2]
Ceritinib + Trametinib	DCF017N	Trametinib	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[2]
Ceritinib + Trametinib	DC6LJTA	Trametinib	Embryonal rhabdomyosarcoma (Cell Line: RD)	[2]
Ceritinib + JQ1	DC1GI3P	JQ1	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[2]
Ceritinib + JQ1	DCR4V0P	JQ1	Embryonal rhabdomyosarcoma (Cell Line: RD)	[2]
Ceritinib + PMID25656651-Compound-5	DCMUK17	PMID25656651-Compound-5	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[2]
Ceritinib + Ceritinib	DC6W1GN	Ceritinib	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[2]
Ceritinib + Ceritinib	DCY49EX	Ceritinib	Embryonal rhabdomyosarcoma (Cell Line: RD)	[2]
Ceritinib + BMS-754807	DCIJ9RY	BMS-754807	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[2]
Ceritinib + MK-2206	DCQPSJ6	MK-2206	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[2]
Everolimus + Ceritinib	DCDYWSN	Everolimus	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[3]
Everolimus + Ceritinib	DCFVD8M	Everolimus	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[3]
Everolimus + Ceritinib	DC3T6MH	Everolimus	Embryonal rhabdomyosarcoma (Cell Line: RD)	[3]
GSK2126458 + Ceritinib	DCMISIV	GSK2126458	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[2]
GSK2126458 + Ceritinib	DCSNPVP	GSK2126458	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[2]
GSK2126458 + Ceritinib	DCFD6FY	GSK2126458	Embryonal rhabdomyosarcoma (Cell Line: RD)	[2]
SCH772984 + Ceritinib	DC4AXJX	SCH772984	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[2]
SCH772984 + Ceritinib	DC8CEXO	SCH772984	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[2]
SCH772984 + Ceritinib	DCL2N4F	SCH772984	Embryonal rhabdomyosarcoma (Cell Line: RD)	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 25 DrugCom(s)

6 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Ceritinib + Warfarin	DCN801X	Warfarin	ALK-positive Advanced Tumors	[4]
Ceritinib + LEE011	DC3QIP4	LEE011	Non-small Cell Lung Cancer	[5]
Ceritinib + Docetaxel	DCSDTVC	Docetaxel	Non-small Cell Lung Cancer	[6]
Everolimus + Ceritinib	DC8BYYT	Everolimus	ALK Positive	[7]
Trametinib + Ceritinib	DCKQWQ1	Trametinib	Non-small Cell Lung Cancer	[8]
Brigatinib + Ceritinib	DCJW560	Brigatinib	Lung Non-Squamous Non-Small Cell Carcinoma	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DrugCom(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7397).
2	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
3	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4	ClinicalTrials.gov (NCT02422589) A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors
5	ClinicalTrials.gov (NCT02292550) Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.
6	ClinicalTrials.gov (NCT03611738) Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
7	ClinicalTrials.gov (NCT02321501) Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
8	ClinicalTrials.gov (NCT03087448) Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
9	ClinicalTrials.gov (NCT03737994) Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer